Cancer Clinical Trials

Participating in a clinical trial can be a life-changing experience. When you join a clinical trial, you not only take an active role in fighting your own cancer, but you also help researchers and scientists develop new medications and treatments to help other cancer patients live longer.

At The Christ Hospital Health Network, we are recognized as a national leader in clinical research and for best practice standards in patient care. Our research and innovation has led to breakthrough medical advances and improved outcomes for nearly 40 years.

Every day, our doctors and researchers work to find cures for cancer - but we don't do it alone. Our patients play an essential role in finding better ways to prevent, diagnose and treat cancer.

 

Promising new therapies for cancer

Our clinical trials are conducted at various locations including:

  • The Christ Hospital Cancer Center

  • The Christ Hospital Physicians - Hematology & Oncology

  • The Christ Hospital Physicians - Surgical Oncology

  • Other clinical sites throughout Greater Cincinnati

We average 15 active studies, from phase I though phase IV. Phases are steps that clinical trials go through. If a new treatment is successful in one phase, it moves on to testing in the next phase.

Search our clinical trials

Find a clinical trial that is right for you. Below is a categorized list (alphabetical by cancer type) of all of our studies updated monthly so you know you're getting the latest information available. All of the following trials are currently recruiting. To refer a patient or enroll in a currently recruiting cancer cohort, call a research nurse at the Lindner Research Center at 513-585-0844.

  • Breast Cancer

  • Colon Cancer

  • Head & Neck Cancer

  • Lung Cancer

  • Leukemia/Lymphoma

Breast Cancer

NCT02488967

NRG-BR003 NCT-#02488967, is a Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer. The purpose of this trial is to determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the invasive disease-free survival (IDFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer.

NCT03418961

SWOG 1501 NCT-#03418961, is a Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic Her-2+ Breast Cancer, Phase III. The purpose of this study is to assess whether prophylactic beta blocker therapy with Carvedilol compared with no prophylaxis reduces the risk of subsequent cardiac dysfunction in patients with metastatic breast cancer receiving trastuzumab-based HER-2 targeted therapy.

NCT01872975

NSABP B-51/RTOG 1304, is a Phase III, multicenter, randomized post neoadjuvant therapy trial, to evaluate whether the addition of chest wall and regional nodal external radiation therapy (XRT) after mastectomy, or, breast and regional nodal XRT after breast conserving surgery, will significantly reduce the rate of events for invasive breast cancer recurrence-free interval in patients who present with histologically positive axillary nodes but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.

NCT01901094

A011202 Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. This study will evaluate whether radiation therapy is as effective as lymph node dissection.

NCT01905046

A211102 Metformin Hydrochloride in Preventing Breast Cancer in Patients with Atypical Hyperplasia or In Situ Breast Cancer

The purpose of this research study is to test whether metformin, a drug commonly used to treat diabetes, is able to get rid of atypia (early cell changes that are thought to be a marker of breast cancer risk) in women at increased risk for breast cancer. There will be testing for the presence of atypia in the breast after metformin is given to see if it can get rid of atypia. The study will compare the effects, good and/or bad, of metformin or placebo on atypia to find out which is better. 

Note: The standard drug used for the "breast cancer prevention" is tamoxifen. If the patient is eligible to take tamoxifen, he/she must be offered tamoxifen prevention as part of clinical care. Metformin and tamoxifen are not similar and function differently. This study is not investigating the use of tamoxifen. Metformin is not approved for preventing breast cancer, but is currently being tested to determine if it can prevent breast cancer.

NCT02750826

A011401 Randomized Phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer

This study is being done to see if losing weight may help prevent breast cancer from coming back (recurring). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed.

Colon Cancer

NCT02912559

A021502 A Randomized Trial of Standard Chemotherapy Alone Or Combined With Atezolizumab As Adjuvant Therapy For Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair.

This study evaluates whether the addition of immune therapy to usual FOLFOX chemotherapy can improve patient outcome compared to FOLFOX alone. 

The immune therapy drug, atezolizumab, may allow ones immune system to do a better job of attacking the cancer cells in the body.

NCT01349881

A0820 A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage0-III Colon  or Rectal Cancer, Phase III preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES).

Head & Neck Cancer

NCT03237325

A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck. Protocol Number:  IDR-OM-02-USA. The purpose of this study is to assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving fractionated radiation treatments and concomitant cisplatin chemotherapy, given as 80-100 mg/m2 every third week, for the treatment of squamous cell carcinoma of the oral cavity or oropharynx.

Lung Cancer

NCT02477826

BMS CA209816 is a randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in early stage non-small cell lung cancer. The purpose of this study is to test the effectiveness safety, and tolerability of Nivolumab in combination with Ipilimumab or Nivolumab in combination with platinum doublet chemotherapy as compared to platinum doublet chemotherapy alone in subject with non-small cell lung cancer. 

Leukemia/Lymphoma

NCT03420183

Oncternal CIRM-001 is a Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies. Cirmtuzumab is a novel therapeutic monoclonal antibody that targets ROR1, an onco-embryonic factor, expressed at high levels on CLL/SLL, MCL, and other tumors but not on normal adult tissues Nonclinical data support the development of cirmtuzumab together with ibrutinib to enhance antitumor activity, overcome disease resistance, and improve both short- and long-term outcomes for patients with CLL/SLL and MCL. The purpose of this study is to evaluate the safety and effectiveness of Cirmtuzumab, an investigational drug, which currently is not approved by the FDA.  It will be looked at alone as a single agent and in combination with ibrutinib, an FDA approved drug, in treating CLL/SLL or MCL.